Stock data
| Market cap. | US$87.2m |
| Last close | US$2.25 |
| High / Low (52 weeks) | US$3.3 / US$1.8 |
| Stock market listing | NASDAQ |
| Forecast net cash (US$m) | 9.9 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 0.4018 | 21.5676 | (20.2482) |
| Relative * | 3.7947 | 24.6178 | (19.9671) |
* % Relative to local index
Other companies covered in sector
| Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2010A | 0.3 | (11.4) | (11.6) | (39.7) | N/A | N/A |
| 2011A | 0.0 | (28.4) | (29.0) | (75.1) | N/A | N/A |
| 2012E | 0.0 | (32.5) | (37.1) | (96.0) | N/A | N/A |
| 2013E | 0.0 | (35.4) | (41.1) | (106.4) | N/A | N/A |
Last updated on 17/04/2012
Latest research
Critical capital injection
Review | Pharmaceutical & Healthcare | 23/03/2012
Leg-saving cell therapy
Outlook | Pharmaceutical & Healthcare | 24/10/2011
Investment summary
After the presentation of full Phase II RESTORE critical limb ischaemia (CLI) data, Aastrom is entering a quiet news period. The company aims to market directly in the US; we assume an EU partnering deal and 2013 upfront. The Q112 $40m funding enables the REVIVE Phase III for CLI to progress but will be insufficient to complete development. Aastrom has a leading position in stem cell therapy and deals in 2012 are possible.
Last updated on 23/04/2012
Industry outlook
The 72-patient Phase II RESTORE CLI data showed a statistically significant reduction in the combined amputation and amputation-related risk factor endpoint (p=0.0032). The pivotal REVIVE Phase III in 594 patients has been FDA agreed under an SPA and started in Q112. If it meets its 12-month endpoint, Ixmyelocel-T should be the first marketed cell therapy for CLI and the only US treatment option for 100,000-150,000 potential amputees per year. In ischaemic dilated cardiomyopathy, a Phase IIa indicated good safety and some responses.
Last updated on 23/04/2012
Key management
| Tim Mayleben, CEO |
| Brian Gibson, FD |
Company address
| Domino's Farms Lobby K, 24 Frank Lloyd Wright Drive Ann Arbor 48105 United States (734) 418-4400 View website |
